REVELATION BIOSCIENCES INC (NASDAQ: REVB)

Introduction

Revelation Biosciences Inc. is a clinical-stage biotechnology company headquartered in San Diego, California. Founded in 2020, the company develops Gemini, an intravenous formulation of phosphorylated hexaacyl disaccharide (PHAD®) designed to modulate the innate immune system and address inflammatory damage in conditions such as trauma, infection, and organ injury.

Corporate Structure

• Headquarters: San Diego, CA
• Founded: 2020
• Employees: 11–50 (LinkedIn)
• Exchange: NASDAQ (Ticker: REVB)
• Management Changes:
  • On May 28, 2025, Revelation filed a Form 8-K under Item 5.02 reporting changes in officers and directors and under Item 8.01 reporting other corporate events.

Product Pipeline

Program	Indication	Stage
GEMINI-AKI	Acute kidney injury	Preclinical data + Phase 1
GEMINI-CKD	Chronic kidney disease	Preclinical studies
GEMINI-PSI	Post-surgical and catheter-related infection	Preclinical data
GEMINI-PBI	Infection prevention in severe burn patients	Newly announced (April 29, 2025)

• Phase 1 Data: The primary safety endpoint was met with statistically significant upregulation of the anti-inflammatory biomarker IL-10 observed.
• New Indication: On April 29, 2025, Revelation announced the GEMINI-PBI program aimed at preventing infection in hospitalized burn patients, expanding its collaboration with Vanderbilt University.

Recent Developments and News

• May 29, 2025: Filed a prospectus (Form 424B3) offering 675,000 shares of common stock at $1.10 per share, which includes Class H warrants exercisable at $1.10 for five years; Roth Capital Partners was engaged as the placement agent.
• May 28, 2025:
  • Notice of effectiveness of the S-1 registration statement, clearing the way for a “best efforts” offering.
  • Form 8-K documenting officer and director changes (Item 5.02) and other corporate events (Item 8.01).
• January 28, 2025: Completed a 1-for-16 reverse stock split.
• January 25, 2024: Completed a 1-for-30 reverse stock split.

Financial and Strategic Analysis

Stock and Market Data (as of 2025-05-29)

• Price: $0.9393 (–51.33% intraday)
• Volume: 344,758 shares
• 52-Week Range: $0.8616–$60.80
• Market Cap: $1.86 M
• Enterprise Value: –$1.84 M
• Beta (5Y): 0.19

Valuation and Profitability

• Price/Book (mrq): 0.65
• Net Income (TTM): –$14.41 M
• EPS (TTM): –82.07
• Total Cash (mrq): $3.7 M
• Levered Free Cash Flow (TTM): –$9.17 M

Strategic Outlook

• The capital raised from the 424B3 offering is intended to support ongoing R&D and clinical progress.
• Reverse stock splits are part of strategies aimed at maintaining NASDAQ listing compliance and enhancing trading liquidity.
• Collaboration with academic partners, including Vanderbilt University, extends the pipeline into indications related to burn infections and surgical prophylaxis.

Market Position and Industry Context

• Sector: Biotechnology Research, with a focus on immunomodulation and innate immune response modulation.
• Scale: Small-cap clinical-stage company experiencing limited revenue and a high R&D expenditure rate.
• Competition: Biotech firms developing immunomodulatory or anti-inflammatory therapies for acute and chronic conditions.
• Differentiator: Proprietary PHAD®-based platform with multiple indications addressing kidney injury, surgical prophylaxis, and burn-related infections.

TL;DR

• Filed a Form 424B3 offering 675,000 shares at $1.10 plus warrants on May 29, 2025.
• The S-1 registration became effective on May 28, 2025, alongside an 8-K reporting management changes.
• Launched the GEMINI-PBI program on April 29, 2025, targeting infection prevention in severe burn patients.
• Stock trades at approximately $0.94 with a $1.86 M market cap; net cash approximately $3.7 M.
• Key catalyst includes ongoing clinical development of Gemini across multiple indications and expected updates in August 2025.